Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with AgiosAvanzanite is ...
Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration of earlier ropeginterferon ...
Law Offices of Howard G. Smith announces an investigation on behalf of Phreesia Inc. (“Phreesia” or the “Company”) (NYSE: PHR) investors concerning the Company’s possible violations of federal ...
SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three ...
UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBCCULVER CITY, Calif ...
Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with no concurrent financing or share offering planned STOCKHOLM, SWEDEN ...
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for ...
Medical Care Technologies Inc. (OTC Pink:MDCE) Previews MDCE Melanoma Scan Beta on Corporate Website
MDCE Strengthens Its Artificial Intelligence Expansion Strategy With New Healthcare Beta Preview and Multi-Sector Growth Initiatives MESA, AZ / ACCESS Newswire / May 22, 2026 / Medical Care ...
Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, ...
Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...
LUND, SE / ACCESS Newswire / May 22, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on a recent update shared by Shanghai Henlius Biotech, Inc. regarding long-term follow-up ...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results